Lenalidomide, an antiproliferative CLL drug

Blood. 2014 Sep 4;124(10):1545-6. doi: 10.1182/blood-2014-07-587360.

Abstract

In this issue of Blood, Fecteau et al show that lenalidomide inhibits proliferation of chronic lymphocytic leukemia (CLL) cells in vitro by targeting cereblon. Thus far, the clinical activity of this drug in CLL was believed to be mainly via the microenvironment.

Publication types

  • Comment

MeSH terms

  • Adaptor Proteins, Signal Transducing
  • Angiogenesis Inhibitors / pharmacology*
  • Cell Proliferation / drug effects*
  • Cyclin-Dependent Kinase Inhibitor p21 / physiology*
  • Humans
  • Lenalidomide
  • Leukemia, Lymphocytic, Chronic, B-Cell / pathology*
  • Peptide Hydrolases / physiology*
  • Thalidomide / analogs & derivatives*
  • Thalidomide / pharmacology
  • Ubiquitin-Protein Ligases

Substances

  • Adaptor Proteins, Signal Transducing
  • Angiogenesis Inhibitors
  • CDKN1A protein, human
  • CRBN protein, human
  • Cyclin-Dependent Kinase Inhibitor p21
  • Thalidomide
  • Ubiquitin-Protein Ligases
  • Peptide Hydrolases
  • Lenalidomide